Replies to post #294473 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

it wasn't "BURIED".

First, they clearly informed the readers that the primary endpoint was PFS:

Methods
After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n?=?232) or temozolomide and placebo (n?=?99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS).

Second, as Senti already pointed out, the authors said PFS was the primary endpoint (no hiding or burying here) and straightforwardly informed readers it had not been evaluated for the publication and why that was the case? Of course, this is info we all know. You need more material. lol.

Statistical analyses
The study’s primary endpoint is PFS, and the secondary endpoint is OS. PFS has not yet been evaluated for this publication and will be the subject of later analyses to allow for central, multi-factorial assessment by an expert panel, using criteria currently emerging as appropriate for immune therapy in this patient population where progression can be complex to determine and pseudo-progression is a known confounding phenomenon. Analysis of the blinded interim data on OS of the ITT population (using SAS version 9.4) was performed 34 months after the midpoint of patient enrollment, and 16 months after the last patient was enrolled and randomized.

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6